Biotech

A two-day in person event packed with leading speakers, research and cutting-edge presentations on RNA-based therapeutic medicines, formulation and delivery of mRNA, RNAi and siRNA therapeutics. Experience case studies, technical presentations, and interactive discussions on the latest breakthroughs in this promising area of drug development.

Experience the Swiss Biotech Day, a premier biotechnology conference, and join us for an unparalleled gathering of more than 2,500 professionals from the global life sciences community. Explore the latest advancements in R&D, manufacturing, data management, artificial intelligence, and innovative financing.

The Scientific Program features a diverse range of scientific sessions organized into two concurrent themed tracks covering issues such as Novel In Vitro and In Silico Assays to Predict Human Safety, In Vivo and Ex vivo Case Studies For Safety, Debate on the “Value” of Primary Tissue and In Vivo Studies and are disease Models Relevant in Safety Pharmacology, Macro Molecules Science: Antibodies, Oligo, and Peptides, Translation Beyond FIH Exposure Response Models, Macro Molecules Science: Gene therapy, Cell Therapy, mRNA and PROTAC, Derisking and Risk Mitigation Strategies, Clinical Cardiology, and much more! This will ensure attendees can stay abreast of new content and developments in key areas of interest. 

With more than 6,500 toxicologists from all over the world expected to attend, opportunities for networking and finding new collaborators are abundant—from the Scientific Sessions and other daytime events through the evening receptions. Research organizations, government agencies, drug developers, regulatory authorities, academic institutions, laboratory and medical suppliers, or consultants are encouraged to exhibit at ToxExpo.

(2022) Back for its 22nd Annual Edition, this global bio-pharma industry event will address through its programme the main challenges in investment for 2022, partnering and alliance management and prospects for 2023. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. 

Sachs Associates is a long established international conference company, with offices in Switzerland and the UK. SACHS associates runs a limited number of high profile conferences in Europe and the USA, which focuses on Bio- Pharma, Medtech and Digital Health. These conferences focus on licensing and investment opportunities and all provide presenting opportunities for companies’ as well as excellent meeting facilities for all delegates in order to network.  Sachs Associates focuses on the practical benefits accruing from conference participation, the exchange of ideas and information of the facilitating of business transactions.

(2022) The main programme for the 9th Annual HTIF will feature more than 7 hours of high-level speeches and panel discussions. In addition, there will be a global company showcase of 25+ presentations by established public, private, emerging and seed companies, offering innovative solutions and are seeking investment and partnering opportunities. This will include a limited number of live presentations taking place in dedicated presenting tracks, alongside virtual company showcases, which will be available on demand during the virtual week. We anticipate 300+ delegates drawn from Digital Health, MedTech/Device companies, banks, investors and advisors with part of the audience participating virtually. 

ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high-impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Following the success of the previous years, our Roth Conference, with close to 550 participating companies and over 5,100 attendees, will feature presentations from public and private companies in a variety of sectors.

We are excited to the Rocky Mountain Life Science Investor & Partnerships to return in 2022! Investors and strategic partners converge in the Colorado mountains on a biennual basis to learn about new breakthroughs coming out of the Rocky Mountain region. Colorado BioScience Association leads the biennial event, attracting high-profile angel investors, venture capitalists, and representatives from large life sciences companies to meet leaders from emerging and established life science companies from Arizona, Colorado, Montana, New Mexico and Utah.

The RDD conference series impacts regulatory and scientific policies worldwide and is recognized as one of the premier international meetings in this area. Its success is founded on the selection of internationally renowned speakers addressing salient topics in pulmonary and nasal drug delivery, lively audience participation, and the financial support of organizations with a proven commitment to, and record of, innovation in the field of inhalation aerosols.